P4, N=76, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jun 2026 --> Jan 2027

P2, N=75, Recruiting, Institut de cancérologie Strasbourg Europe | Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Jul 2029 | Trial primary completion date: Mar 2027 --> Jul 2028

In vitro, FAM172A promoted malignant behavior and conferred resistance to cisplatin...These findings highlight FAM172A as a critical promoter of EOC progression, associated with aggressive tumor characteristics and treatment failure. By activating the PI3K-Akt pathway, FAM172A represents a promising therapeutic target for EOC, potentially offering new strategies to improve patient outcomes, particularly in overcoming chemoresistance.

The patient remained recurrence-free at 11 months of follow-up after gemcitabine bladder infusion chemotherapy, arterial drug-infusion embolization, systemic chemotherapy, and immunotherapy.

In summary, the dacarbazine-2-AEH2P combination exhibits synergistic pharmacodynamic activity that enhances cytotoxicity through coordinated modulation of proliferative and apoptotic pathways. These findings highlight its potential as a promising strategy to improve chemotherapeutic efficacy and overcome resistance in melanoma treatment.

The CHPT1-pSTAT3-SLC7A11 axis governs ferroptosis-dependent chemoresistance in PDAC. Dual targeting of CHPT1 and ferroptosis pathways represents a promising strategy to overcome GEM resistance, highlighting metabolic-kinase crosstalk as a therapeutic vulnerability.

Overall, this study indicates that regulating iron homeostasis to inhibit ferroptosis is related to the therapeutic effect of 6-gingerol against CINV.

Gemcitabine-cisplatin remains effective and tolerable in metastatic GBC. Despite the emergence of Gemcitabine-Cisplatin with durvalumab as new standard, this prospective dataset provides valuable real-world outcomes from a high-incidence region with limited access to immunotherapy.

RNA sequencing analysis demonstrated that NP3 synergistically promoted tumor regression by concurrently inducing pro-apoptotic signaling and immune responses. In conclusion, this study presents an innovative therapeutic strategy combining targeted chemotherapy delivery with robust antitumor metalloimmunotherapy, offering a promising therapeutic approach for OS.

P2, N=40, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P=N/A, N=110, Active, not recruiting, Nantes University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Mar 2026 | Trial primary completion date: May 2026 --> Nov 2025

P=N/A, N=150, Not yet recruiting, Rajiv Gandhi Cancer Institute & Research Center, India